METOPROLOL SUCCINATE ER tablet, extended release

Country: মার্কিন যুক্তরাষ্ট্র

ভাষা: ইংরেজি

সূত্র: NLM (National Library of Medicine)

সক্রিয় উপাদান:

METOPROLOL SUCCINATE (UNII: TH25PD4CCB) (METOPROLOL - UNII:GEB06NHM23)

থেকে পাওয়া:

Direct_Rx

প্রশাসন রুট:

ORAL

প্রেসক্রিপশন টাইপ:

PRESCRIPTION DRUG

থেরাপিউটিক ইঙ্গিত:

1.1 Hypertension Metoprolol succinate extended-release tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety

পণ্য সারাংশ:

Tablets containing metoprolol succinat, USP equivalent to the indicated weight of metoprolol tartrate, USP, are white, biconvex, film-coated, and scored on both sides. Shape Engraving Bottle of 90 Bottle of 100 Bottle of 500 Bottle of 1000 25 mg Oval N/25 615-90 615-01 615- 05 615-10 50 mg Round N/50 616-90 616-01 616- 05 616-10 100 mg Round N/100 617-90 617-01 617- 05 617-10 200 mg Oval N/200 618-90 618-01 618- 05 618-10 Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]

অনুমোদন অবস্থা:

Abbreviated New Drug Application

পণ্য বৈশিষ্ট্য

METOPROLOL SUCCINATE ER- METOPROLOL SUCCINATE ER TABLET, EXTENDED
RELEASE
DIRECT_RX
----------
METOPROLOL SUCCINATE ER
Following abrupt cessation of therapy with certain beta-blocking
agents,
exacerbations of angina pectoris and, in some cases, myocardial
infarction have
occurred. When discontinuing ...
WARNING: ISCHEMIC HEART DISEASE:
Following abrupt cessation of therapy with certain beta-blocking
agents,
exacerbations of angina pectoris and, in some cases, myocardial
infarction have
occurred. When discontinuing chronically administered metoprolol
succinate
extended-release tablets, particularly in patients with ischemic heart
disease, the
dosage should be gradually reduced over a period of 1 - 2 weeks and
the patient
should be carefully monitored. If angina markedly worsens or acute
coronary
insufficiency develops, metoprolol succinate extended-release tablet
administration
should be reinstated promptly, at least temporarily, and other
measures
appropriate for the management of unstable angina should be taken.
Warn
patients against interruption or discontinuation of therapy without
the physician's
advice. Because coronary artery disease is common and may be
unrecognized, it
may be prudent not to discontinue metoprolol succinate
extended-release tablet
therapy abruptly even in patients treated only for hypertension (5.1).
1.1 Hypertension
Metoprolol succinate extended-release tablets are indicated for the
treatment of
hypertension, to lower blood pressure. Lowering blood pressure lowers
the risk of fatal
and non-fatal cardiovascular events, primarily strokes and myocardial
infarctions. These
benefits have been seen in controlled trials of antihypertensive drugs
from a wide variety
of pharmacologic classes including metoprolol.
Control of high blood pressure should be part of comprehensive
cardiovascular risk
management, including, as appropriate, lipid control, diabetes
management,
antithrombotic therapy, smoking cessation, exercise, and limited
sodium intake. Many
patients will require more than 1 drug to achi